Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.62 |
| ▸ | ACE | P12821 | 5/20 | 0.62 |
| ▸ | CPA1 | P15085 | 2/20 | 0.62 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779203 | 1.00 | MME (0.62) | MMEACECPA1ACE2CA2 | |
| SCHEMBL1519727 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29436862 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL3821361 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29401906 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29397962 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL1519731 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL29481445 | 0.87 | CTSS (0.74) | MMEACECPA1ACE2CA2 | |
| SCHEMBL607215 | 0.86 | MME (0.65) | MMEACECPA1ACE2CA2 | |
| SCHEMBL8712438 | 0.86 | MME (0.65) | MMEACECPA1ACE2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| EP-1877091-B1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | TAIMED BIOLOG INC (TW) | 2015-03-25 | — | — | EP | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| EP-2258680-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-19 | — | — | EP | disclosed |
| US-8227450-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILIA BIOPHARMA INC. (CA) | 2012-07-24 | — | — | US | disclosed |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2012-03-01 | — | — | US | disclosed |
| US-8008297-B2 | (1-{5-[(4-amino-benzenesulfonyl)-isobutyl-amino]-6-phosphonooxy-hexacarbomoyl}-2,2-diphenyl-ethyl)-carbamic acid methyl ester; which upon cleavage of cleavable bond or unit generates HIV-1 aspartyl protease inhibitor; antiviral agent; good solubility, and bioavailability; HIV or HTLV infection | AMBRILIA BIOPHARMA INC. (CA) | 2011-08-30 | — | — | US | disclosed |
| EP-2258680-A2 | Aromatic derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258681-A2 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | Ambrilia Biopharma Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-20100130765-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | AMBRILIA BIOPHARMA INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| EP-2165709-A2 | Lysine based compounds | Ambrilia Biopharma Inc. (CA) | 2010-03-24 | — | — | EP | disclosed |
| US-20090253926-A1 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILLA BIOPHARMA INC. (CA) | 2009-10-08 | — | — | US | disclosed |
| EP-1773763-B1 | LYSINE BASED COMPOUNDS | AMBRILIA BIOPHARMA INC (CA) | 2008-12-17 | — | — | EP | disclosed |
| US-20080269172-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2008-10-30 | — | — | US | disclosed |
| US-7388008-B2 | Lysine based compounds | AMBRILIA BIOPHARMA INC. (CA) | 2008-06-17 | — | — | US | disclosed |
| EP-1877091-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | Ambrilia Biopharma Inc. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | MME 1749/4885ACE 1102/4885CPA1 2048/4885 |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | MME 53/4885ACE 78/4885CPA1 90/4885 |
| US-20090253926-A1 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | PREP, SPINT2, DNPEP | MME 50/4885ACE 36/4885CPA1 116/4885 |
| US-20120053139-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | MME 53/4885ACE 78/4885CPA1 90/4885 |
| US-20080269172-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | MME 1749/4885ACE 1102/4885CPA1 2048/4885 |
| US-20100130765-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | PREP, SPINT2, HPN | MME 52/4885ACE 42/4885CPA1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.